These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2222 related items for PubMed ID: 33838391

  • 1. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2021 Apr 30; 4(4):CD013257. PubMed ID: 33930176
    [Abstract] [Full Text] [Related]

  • 4. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ.
    J Immunother Cancer; 2021 Apr 30; 9(4):. PubMed ID: 33827906
    [Abstract] [Full Text] [Related]

  • 5. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H, Han KD, He ZJ, Huang YS.
    Technol Cancer Res Treat; 2021 Apr 30; 20():15330338211033498. PubMed ID: 34323149
    [Abstract] [Full Text] [Related]

  • 6. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M.
    Cancer Chemother Pharmacol; 2020 Jan 30; 85(1):121-131. PubMed ID: 31745593
    [Abstract] [Full Text] [Related]

  • 7. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul 30; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 8. Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.
    Zhong J, Xiong D, Liu Y, Yuan S.
    Thorac Cancer; 2024 Jan 30; 15(2):152-162. PubMed ID: 38010059
    [Abstract] [Full Text] [Related]

  • 9. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.
    Ann Oncol; 2018 Jun 01; 29(6):1437-1444. PubMed ID: 29617710
    [Abstract] [Full Text] [Related]

  • 10. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
    Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Lung Cancer; 2020 Jan 01; 139():140-145. PubMed ID: 31786476
    [Abstract] [Full Text] [Related]

  • 11. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ, Ren A, Zheng L, Zheng ED, Jiang T.
    Front Immunol; 2021 Jan 01; 12():651086. PubMed ID: 34248939
    [Abstract] [Full Text] [Related]

  • 12. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O, CLICaP.
    Thorac Cancer; 2020 Sep 01; 11(9):2552-2560. PubMed ID: 32705787
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L.
    Front Immunol; 2021 Sep 01; 12():731546. PubMed ID: 34484242
    [Abstract] [Full Text] [Related]

  • 14. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C.
    Front Immunol; 2021 Sep 01; 12():716317. PubMed ID: 34777340
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, Kaira K, Kaburagi T, Minato K, Kobayashi K, Kagamu H.
    Cancer Med; 2021 Oct 01; 10(20):6971-6984. PubMed ID: 34414673
    [Abstract] [Full Text] [Related]

  • 16. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.
    JAMA Netw Open; 2023 Jul 03; 6(7):e2322915. PubMed ID: 37432682
    [Abstract] [Full Text] [Related]

  • 17. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, Liu D, Li W.
    J Cell Physiol; 2020 May 03; 235(5):4913-4927. PubMed ID: 31693178
    [Abstract] [Full Text] [Related]

  • 18. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S.
    PLoS One; 2021 May 03; 16(6):e0252537. PubMed ID: 34061904
    [Abstract] [Full Text] [Related]

  • 19. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C.
    Lung Cancer; 2019 Apr 03; 130():10-17. PubMed ID: 30885328
    [Abstract] [Full Text] [Related]

  • 20. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
    Shimoda Y, Yoshida T, Shirasawa M, Mizuno T, Jo H, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y, Motoi N.
    Anticancer Res; 2021 Nov 03; 41(11):5739-5747. PubMed ID: 34732447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 112.